- Conditions
- Type 2 Diabetes (T2D)
- Interventions
- NNC0487-0111 subcutanous, Placebo (NNC0487-0111 subcutanous), NNC0487-0111 oral, Placebo (NNC0487-0111 oral)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 30 more
Location Directory
Clinical trials in Orlando, Florida
This page shows live ClinicalTrials.gov search results for Orlando, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
6861
Shown on this page
12
Current sort
Recently updated
Location scope
Orlando, FL
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 685–696 of 6,861 matching trials in Orlando, FL.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
- Interventions
- rezatapopt, pembrolizumab
- Drug
- Lead sponsor
- PMV Pharmaceuticals, Inc
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 32
- States / cities
- Irvine, California • La Jolla, California • Los Angeles, California + 26 more
- Conditions
- Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
- Interventions
- Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, High-Dose-Rate Vaginal Cuff Brachytherapy, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Multigated Acquisition Scan, Paclitaxel, Survey Administration, Trastuzumab/Hyaluronidase-oysk
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 409
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 307 more
- Conditions
- Moderate Alzheimer Disease
- Interventions
- SNK01, Placebo
- Biological · Other
- Lead sponsor
- NKGen Biotech, Inc.
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 7
- States / cities
- Glendale, California • Santa Ana, California • Tarzana, California + 4 more
- Conditions
- Moderately to Severely Active Ulcerative Colitis
- Interventions
- Afimkibart, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 64
- States / cities
- Dothan, Alabama • Scottsdale, Arizona • Sun City, Arizona + 52 more
- Conditions
- Obesity or Overweight
- Interventions
- AZD6234, Placebo comparator
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 23
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 19 more
- Conditions
- Acute Ischemic Stroke
- Interventions
- MT+CAS with IV-AP, MT+CAS with PO-AP, MT+CAT with PO-AP
- Procedure
- Lead sponsor
- Mercy Health Ohio
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 60
- States / cities
- Mobile, Alabama • Glendale, California • Irvine, California + 54 more
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
- Interventions
- BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 5,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 229
- States / cities
- Athens, Alabama • Cullman, Alabama • Fairhope, Alabama + 189 more
- Conditions
- Grade 2 Meningioma, Intracranial Meningioma
- Interventions
- Biospecimen Collection, Clinical Observation, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Proton Beam Radiation Therapy, Quality-of-Life Assessment
- Procedure · Other · Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2032
- U.S. locations
- 198
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 162 more
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
- Interventions
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Diagnostic Imaging Testing, Inotuzumab Ozogamicin, Leucovorin Calcium, Lumbar Puncture, Methotrexate, Pegaspargase, Vincristine
- Drug · Procedure · Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 156
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 127 more
- Conditions
- Osteoporosis, Postmenopausal
- Interventions
- TVB-009, Prolia®
- Combination Product
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 60 Years to 90 Years · Female only
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Tucson, Arizona • San Diego, California + 17 more
- Conditions
- Focal Onset Seizures
- Interventions
- SPN-817, Placebo
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more